Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > IMMUSAFE.COM
View:
Post by TopBroker on Apr 20, 2021 12:06pm

IMMUSAFE.COM

This was sent to me by one of your shareholders and a question why this was not disclosed to the shareholders as a news release on the state of the Companies ongoing joint venture. SEC rules are specific as to disclosure and I find it reprehensible that your over paid, under qualified management does not look after the shareholders best interest. There must be a reason to keep this stock from underperforming. You need a board change badly.

https://immusafe.com/
Comment by DavidKingCanada on Apr 20, 2021 12:33pm
Please keep in mind PMN is searching for a new CEO by years end. There will be more changes coming to upper Managment. At the current price this Company is a Buy and Hold for now. Don't worry too much about the few cents up and down. If and when Aducanumb is approved, this Stock will go up. 
Comment by Mole101 on Apr 20, 2021 12:41pm
Wow !! I see it as a great progress and a source of future revenue for PMN , the website it's not finished and no sales are taking place at this time, likely they are not ready to go and waiting for few more approvals.  I see it as proactive and looks like it's run by BCNI do it will be ontheir time frame and ones ready   
Comment by M101 on Apr 20, 2021 12:50pm
Finally,, something which Goldstein can't FUp
Comment by M101 on Apr 20, 2021 12:42pm
Isn't that just putting a brand name to the JV announced last year?
Comment by goldtech on Apr 20, 2021 12:45pm
I read all the approvals are complete and talking to their lab sales have been brisk.
Comment by M101 on Apr 20, 2021 1:01pm
Must be pro sports teams and business class passengers https://immusafe.com/pricing/
Comment by BrokenPromis on Apr 20, 2021 4:52pm
Sorry I just saw this website.  What technology/IP is from Promis?   Surface PlasmonResonance? Do we know this isn't all BCNL's development?
Comment by Mole101 on Apr 20, 2021 5:16pm
b) Joint arrangement 2 (JV2) will provide the service of highly sensitive and specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 virus that is responsible for COVID-19. JV2 includes a jointly controlled venture (Immusafe Labs, Inc.) and jointly controlled operations. The company acquired 50% of Immusafe Labs, Inc. for $3,000. The company is ...more  
Comment by DavidKingCanada on Apr 20, 2021 10:45pm
This is great news for the future of PMN
Comment by M101 on Apr 20, 2021 7:33pm
Comment by BrokenPromis on Apr 21, 2021 12:29pm
M101 - I bought into the "Promise" of best-in-class a couple of years ago.  I have what for me is a lot of money in this company.  Some of it as high as $0.42 usd.  I used to believe them when they talked about clinical trials.  I was also excited when they talked about the JV.  But the absolute reality is that the ONLY delivery so far has been a dilution.  ...more  
Comment by M101 on Apr 21, 2021 12:46pm
I share your skepticism, but it should be obvious to any investor (not traders) that SPR is a technology that could not possibly have come from Promis.  
Comment by BrokenPromis on Apr 21, 2021 1:03pm
Yeah, that was kind of the point i was trying to make.  I did not see anything on that website that pointed me to something Promis had contributed.  I am assuming it is in there - that it is Promis IP that is differentiating what they are doing.  But I did not see any mention of propriatary technology based on what we are doing...
Comment by M101 on Apr 21, 2021 3:33pm
See news released 2020 May 19 & 28, and  June 17. I include May 28, the supercluster award for Plotkin's work on covid evolution only because it seems logical that the JV is going to want to stay ahead of the curve re variants.   
Comment by Speyeder999 on Apr 21, 2021 4:07pm
Speaking of Plotkin, does anyone know if he's still on Promis's management team?I think a poster alluded to the fact that he is no longer on board. That would strike me as strange, no? Furthermore, unless I'm mistaken, I find it odd that he doesn't appear to be holding any shares of the company (again, I may be mistaken on this) but I seem to be notice everyone else as owning ...more  
Comment by Mole101 on Apr 21, 2021 4:39pm
  https://promisneurosciences.com/team/ Steven Plotkin, PhD Chief Physics Officer Prof. Steven Plotkin is a theoretical and computational biophysicist whose research focuses on protein folding and misfolding in neurodegenerative disease, protein evolution and cellular differentiation, and the molecular mechanisms of cancer. He has been a professor at UBC in the Department of Physics ...more  
Comment by Speyeder999 on Apr 21, 2021 6:42pm
Thanks Mole,  Anyway of finding out if he's still a shareholder. Reason I'm asking is James Kupiec seemed to have exited as our Chief Medical Officer without a mention last December without a mention from the company nor a mention in the year end report to become Chief Clinical Developer at Cassava. He seems to be holding on the 2,5 millions shares or so, unlesss he unloaded them ...more  
Comment by Gbathat on Apr 20, 2021 8:36pm
TB, thanks for sharing this!!!!!!   Hopefully we get a PR soon.  This looks very exciting.
Comment by Gbathat on Apr 20, 2021 10:20pm
I think there will be high demand for this test.  IgG sub-classes... nice. Also, check out the example report at https://immusafe.com/our-technology/  (scroll down and click on pdf window to see the report).  It tells you your avidity to different variants and provides travel recommendations. Talk about timely.
Comment by Normandt1965 on Apr 21, 2021 1:58pm
I followed the link this morning and it worked....but now it's password protected. ////////// I think there will be high demand for this test. IgG sub-classes... nice. Also, check out the example report at https://immusafe.com/our-technology/ (scroll down and click on pdf window to see the report). It tells you your avidity to different variants and provides travel recommendations. Talk about ...more  
Comment by BottomBroker on Apr 21, 2021 9:13am
So now wait a second here. Does this mean Promis may start to generate....revenue??? Things are getting interesting. 
Comment by Gbathat on Apr 21, 2021 10:05am
at about $160 per test, given the current price on the website and the planned a 50-50 split between PMN and BCNI I wonder if they are keeping this quiet due to potential ongoing non-exclusive licensing negotiations.   If the market for this type of analysis is as big as I hope, and especially if insurance covers these tests in some or all cases, they would need more than one lab ...more  
Comment by Gbathat on Apr 21, 2021 10:06am
correction: $197.50/ test, as each test cost $395USD
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities